vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and P10, Inc. (PX). Click either name above to swap in a different company.
P10, Inc. is the larger business by last-quarter revenue ($81.0M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -4.7%). P10, Inc. produced more free cash flow last quarter ($18.1M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 10.7%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.
PBYI vs PX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $81.0M |
| Net Profit | — | $9.5M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | 31.9% |
| Net Margin | — | 11.7% |
| Revenue YoY | 27.7% | -4.7% |
| Net Profit YoY | — | 79.0% |
| EPS (diluted) | $0.26 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $81.0M | ||
| Q3 25 | $54.5M | $75.9M | ||
| Q2 25 | $52.4M | $72.7M | ||
| Q1 25 | $46.0M | $67.7M | ||
| Q4 24 | $59.1M | $85.0M | ||
| Q3 24 | $80.5M | $74.2M | ||
| Q2 24 | $47.1M | $71.1M | ||
| Q1 24 | $43.8M | $66.1M |
| Q4 25 | — | $9.5M | ||
| Q3 25 | $8.8M | $2.1M | ||
| Q2 25 | $5.9M | $3.4M | ||
| Q1 25 | $3.0M | $4.5M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $20.3M | $1.4M | ||
| Q2 24 | $-4.5M | $7.0M | ||
| Q1 24 | $-4.8M | $5.0M |
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 22.7% | 31.9% | ||
| Q3 25 | 17.6% | 14.1% | ||
| Q2 25 | 12.7% | 24.4% | ||
| Q1 25 | 8.7% | 16.6% | ||
| Q4 24 | 22.6% | 26.9% | ||
| Q3 24 | 27.4% | 11.9% | ||
| Q2 24 | -4.6% | 23.7% | ||
| Q1 24 | -5.3% | 18.3% |
| Q4 25 | — | 11.7% | ||
| Q3 25 | 16.2% | 2.8% | ||
| Q2 25 | 11.2% | 4.7% | ||
| Q1 25 | 6.5% | 6.7% | ||
| Q4 24 | — | 6.2% | ||
| Q3 24 | 25.2% | 1.9% | ||
| Q2 24 | -9.6% | 9.8% | ||
| Q1 24 | -11.0% | 7.6% |
| Q4 25 | $0.26 | $0.08 | ||
| Q3 25 | $0.17 | $0.02 | ||
| Q2 25 | $0.12 | $0.03 | ||
| Q1 25 | $0.06 | $0.04 | ||
| Q4 24 | $0.40 | $0.05 | ||
| Q3 24 | $0.41 | $0.01 | ||
| Q2 24 | $-0.09 | $0.06 | ||
| Q1 24 | $-0.10 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $28.2M |
| Total DebtLower is stronger | $22.7M | $373.2M |
| Stockholders' EquityBook value | $130.3M | $403.5M |
| Total Assets | $216.3M | $928.3M |
| Debt / EquityLower = less leverage | 0.17× | 0.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | $28.2M | ||
| Q3 25 | $94.4M | $40.0M | ||
| Q2 25 | $96.0M | $33.4M | ||
| Q1 25 | $93.2M | $74.4M | ||
| Q4 24 | $101.0M | $67.5M | ||
| Q3 24 | $96.7M | $61.5M | ||
| Q2 24 | $96.8M | $31.2M | ||
| Q1 24 | $107.2M | $29.0M |
| Q4 25 | $22.7M | $373.2M | ||
| Q3 25 | $34.0M | $393.4M | ||
| Q2 25 | $45.3M | $373.0M | ||
| Q1 25 | $56.7M | $357.2M | ||
| Q4 24 | $68.0M | $319.8M | ||
| Q3 24 | $79.3M | $319.4M | ||
| Q2 24 | $90.7M | $300.6M | ||
| Q1 24 | $102.0M | $314.0M |
| Q4 25 | $130.3M | $403.5M | ||
| Q3 25 | $115.3M | $396.8M | ||
| Q2 25 | $104.7M | $388.9M | ||
| Q1 25 | $97.1M | $374.3M | ||
| Q4 24 | $92.1M | $386.9M | ||
| Q3 24 | $71.1M | $394.1M | ||
| Q2 24 | $48.5M | $396.9M | ||
| Q1 24 | $51.0M | $400.1M |
| Q4 25 | $216.3M | $928.3M | ||
| Q3 25 | $202.9M | $936.0M | ||
| Q2 25 | $194.9M | $932.2M | ||
| Q1 25 | $196.2M | $877.4M | ||
| Q4 24 | $213.3M | $869.3M | ||
| Q3 24 | $220.7M | $857.0M | ||
| Q2 24 | $205.0M | $823.2M | ||
| Q1 24 | $214.1M | $832.8M |
| Q4 25 | 0.17× | 0.93× | ||
| Q3 25 | 0.30× | 0.99× | ||
| Q2 25 | 0.43× | 0.96× | ||
| Q1 25 | 0.58× | 0.95× | ||
| Q4 24 | 0.74× | 0.83× | ||
| Q3 24 | 1.12× | 0.81× | ||
| Q2 24 | 1.87× | 0.76× | ||
| Q1 24 | 2.00× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $23.0M |
| Free Cash FlowOCF − Capex | $14.4M | $18.1M |
| FCF MarginFCF / Revenue | 19.1% | 22.3% |
| Capex IntensityCapex / Revenue | 0.0% | 6.0% |
| Cash ConversionOCF / Net Profit | — | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | $14.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $23.0M | ||
| Q3 25 | $9.7M | $-8.6M | ||
| Q2 25 | $14.1M | $13.4M | ||
| Q1 25 | $3.6M | $-4.7M | ||
| Q4 24 | $15.6M | $101.0M | ||
| Q3 24 | $11.0M | $27.5M | ||
| Q2 24 | $1.0M | $34.8M | ||
| Q1 24 | $11.2M | $11.0M |
| Q4 25 | $14.4M | $18.1M | ||
| Q3 25 | $9.7M | $-9.5M | ||
| Q2 25 | $14.1M | $11.6M | ||
| Q1 25 | $3.6M | $-6.0M | ||
| Q4 24 | $15.6M | $96.6M | ||
| Q3 24 | $11.0M | $25.2M | ||
| Q2 24 | $1.0M | $33.9M | ||
| Q1 24 | — | $10.7M |
| Q4 25 | 19.1% | 22.3% | ||
| Q3 25 | 17.7% | -12.6% | ||
| Q2 25 | 26.8% | 15.9% | ||
| Q1 25 | 7.7% | -8.9% | ||
| Q4 24 | 26.4% | 113.6% | ||
| Q3 24 | 13.7% | 34.0% | ||
| Q2 24 | 2.1% | 47.7% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | 0.0% | 6.0% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.1% | 1.9% | ||
| Q4 24 | 0.0% | 5.2% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | 0.4% |
| Q4 25 | — | 2.43× | ||
| Q3 25 | 1.10× | -4.01× | ||
| Q2 25 | 2.41× | 3.96× | ||
| Q1 25 | 1.21× | -1.05× | ||
| Q4 24 | — | 19.12× | ||
| Q3 24 | 0.54× | 19.54× | ||
| Q2 24 | — | 4.98× | ||
| Q1 24 | — | 2.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBYI
Segment breakdown not available.
PX
| Management Fees | $78.1M | 96% |
| Advisory Fees | $1.8M | 2% |
